CRNX

CrineticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$85.00

+160.7% vs current

Most likely

Base case

60%

Probability

Target price

$48.00

+47.2% vs current

B-

Bear case

20%

Probability

Target price

$22.00

-32.5% vs current

AI sentiment snapshot

Latest data as of 2026-01-03

AI commentary

Sentiment is cautiously constructive ahead of key readouts. Investors are split between upside from positive data and downside from binary clinical/funding risks; expect elevated volatility around data releases.

RankAlpha Sentiment AI - 2026-01-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-03catalystNear-term clinical update for lead programHigh impact

Company-disclosed clinical progress update or topline readout for lead endocrine program; date estimated conservatively as Q1 2026 if not specified [#PR-2025-11-01].

2027-01-03catalystRegulatory decision / approval pathway milestoneHigh impact

Potential regulatory filing or approval milestone for a lead therapeutic if late-stage data are positive; assumed window end used for planning and valuation [#10-Kp45].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-03 • Updated nightlySource: Internal modelMethodology